权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Neoantigen-specific T cells in a novel cutaneous squamous cell carcinoma model

新型皮肤鳞状细胞癌模型中的新抗原特异性 T 细胞

基本信息

批准号：
10602966
负责人：
Anngela Christina Adams
金额：
$ 5.27万
依托单位：
UNIVERSITY OF ARIZONA
依托单位国家：
美国
项目类别：
财政年份：
2023
资助国家：
美国
起止时间：
2023-08-01 至 2026-07-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10602966
关键词：
Address Adoptive Transfer Affinity Antibodies Binding Bioinformatics CD4 Positive T Lymphocytes CD8B1 gene Cancer Patient Cells Characteristics Complex Data Dendritic Cells Dermatologist Development Diagnosis Flow Cytometry Foundations Generations Goals Growth Immune Immune checkpoint inhibitor Immunocompetent Immunologics Immunotherapeutic agent Inbred BALB C Mice Injections Irradiated tumor Laboratories Light MHC Class I Genes MHC Class II Genes MHC antigen Malignant Neoplasms Mature T-Lymphocyte Mediating Modeling Mus Mutation Neoplasm Metastasis Nude Mice Outcome Pathway interactions Patients Persons Physiological Research Role Skin Cancer Skin Carcinoma Stains T cell response T-Lymphocyte Techniques Transplantation Vaccinated Vaccination Wild Type Mouse anti-PD-1 anti-PD1 therapy antigen-specific T cells cancer type cancer vaccination comparative efficacy cytotoxic CD8 T cells exome sequencing immunogenic immunogenicity improved improved outcome in vitro testing in vivo innovation melanoma mouse model neoantigen vaccine neoantigens neoplastic cell novel novel drug class prevent programmed cell death protein 1 receptor response skin squamous cell carcinoma success transcriptome sequencing transplant model treatment response tumor tumor growth vaccination strategy vaccine strategy

项目摘要

Abstract: More than one million cases of cutaneous squamous cell carcinoma (cSCC) are diagnosed annually in the US and approximately 4% of patients develop metastases and 2% die of cSCC; thus, a similar number of people die each year from cSCC as melanoma. Immune checkpoint inhibitors (ICI) are a new class of drugs that have transformed the therapy of multiple cancer types, but only half of cSCC patients respond to ICI treatment. ICI target receptors on T cells, such as PD-1, that are expressed after activation and function to turn off T cell responses. The response of cSCC patients to ICI demonstrates the ability of T cells to constrain cSCC growth. However, it remains unclear the extent to which CD8 and, in particular, CD4 T cells contribute to immune-mediated control of cSCC. While the focus of anti-tumor T cell responses has been on MHC class I neoantigens that elicit cytotoxic CD8 T cell responses, there is growing evidence that MHC class II neoantigens eliciting CD4 T cell responses are critical in constraining tumor growth and enhancing response to ICI. Thus, there is a critical need to understand the role of CD8 and CD4 T cells, especially the role of neoantigen-specific T cells, in controlling cSCC growth. We generated a novel physiologic cSCC transplantable model on the BALB/c background from a solar simulated light-induced invasive cSCC tumor. Preliminary data supports that T cells constrain the in vivo tumor growth in the cSCC model and that this model is sensitive to anti-PD-1 treatment. Using bioinformatic approaches with whole exome and RNA sequencing data, we have identified immunogenic MHC class I and II neoantigens predicted to elicit a T cell response based on the binding affinity and presentation of the neoantigen:MHC complex and neoantigen expression. Using melanoma patient data, our lab has previously demonstrated that these characteristics accurately predict the ability of a neoantigen to elicit a T cell response. The central hypothesis is that both neoantigen- specific CD8 and CD4 T cells contribute to immune-mediated control of cSCC growth and response to treatment with vaccination with immunogenic neoantigens alone or in combination with anti-PD-1. To address this hypothesis, we will determine the role of CD8 and CD4 T cells in controlling tumor growth, identify MHC class I and II neoantigens that elicit in vivo T cell responses, and evaluate the expression of functional and inhibitory neoantigen-specific CD8 and CD4 T cells throughout cSCC tumor growth. Then, we will vaccinate mice with dendritic cells loaded with irradiated tumor cells or immunogenic MHC class I and/or II neoantigens and compare the efficacy of these vaccination strategies in inducing CD8 and/or CD4 T cells to prevent cSCC growth and treat cSCC alone or in combination with anti-PD-1. We will demonstrate the requirement for CD8 and/or CD4 T cells through antibody depletion and adoptive transfer. The impact of this project is to 1) identify the contributions of neoantigen-specific CD8 and CD4 T cells in control of cSCC growth and 2) advance the application of personalized neoantigen vaccines to treat cSCC alone or in combination with anti-PD-1.

摘要：每年确诊的皮肤鳞状细胞癌（cSCC）超过100万例